High-dose erythropoietin for tissue protection

European Journal of Clinical Investigation

Volumn 44, Issue 12, 2014, Pages 1230-1238

  Lund, Anton ^a   Lundby, Carsten ^b   Olsen, Niels V ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Rigshospitalet   (Denmark)

Author keywords

Cardioprotection; Erythropoiesis stimulating agent; Erythropoietin; Nephroprotection; Neuroprotection

Indexed keywords

ANTIANEMIC AGENT; CARDIOTONIC AGENT; ERYTHROPOIETIN; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN;

CELL PROTECTION; DRUG EFFECTS; HUMAN; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARDIOTONIC AGENTS; CYTOPROTECTION; ERYTHROPOIETIN; HEMATINICS; HUMANS; KIDNEY DISEASES; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 84912136772     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12357     Document Type: Review

References (59)

1. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007;78:183-205.
2. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141:14-31.
3. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
4. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
5. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 2010;362:189-92.
6. Jelkmann W. Regulation of erythropoietin production. J Physiol 2011;589:1251-8.
7. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994;269:19488-93.
8. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526-31.
9. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044-9.
10. Grasso G. Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage. J Neurosurg Sci 2001;45:7-14.
11. Springborg JB, Ma X, Rochat P, Knudsen GM, Amtorp O, Paulson OB et al. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002;135:823-9.
12. Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T et al. A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 2010;30:961-8.
13. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;91:3974-8.
14. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
15. Vogel V, Kramer HJ, Backer A, Meyer-Lehnert H, Jelkmann W, Fandrey J. Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 1997;10:289-96.
16. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003;100:4802-6.
17. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 2005;19:243-50.
18. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-4.
19. Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 2005;130:877-8.
20. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-6.
21. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-5.
22. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
23. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:e647-56.
24. Yip HK, Tsai TH, Lin HS, Chen SF, Sun CK, Leu S et al. Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Crit Care 2011;15:R40.
25. Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 2007;149:1089-101.
26. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009;111:171-80.
27. Haljan G, Maitland A, Buchan A, Arora RC, King M, Haigh J et al. The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke 2009;40:2769-75.
28. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2011;147:124-31.
29. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010;74:1415-23.
30. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010;74:2365-71.
31. Ludman AJ, Yellon DM, Hasleton J, Ariti C, Babu GG, Boston-Griffiths E et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart 2011;97:1560-5.
32. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011;305:1863-72.
33. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010;3:408-13.
34. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010;31:2593-600.
35. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009;104:1035-40.
36. Aydin Z, Mallat MJ, Schaapherder AF, van Zonneveld AJ, van Kooten C, Rabelink TJ et al. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 2012;12:1793-800.
37. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009;30:253-60.
38. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY et al. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012;13:132.
39. Hafer C, Becker T, Kielstein JT, Bahlmann E, Schwarz A, Grinzoff N et al. High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int 2012;81:314-20.
40. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF Study. Am J Transplant 2010;10:1695-700.
41. Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol 2012;7:1498-506.
42. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76.
43. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8.
44. Rasmussen P, Kim YS, Krogh-Madsen R, Lundby C, Olsen NV, Secher NH et al. Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans. FASEB J 2012;26:1343-8.
45. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009;4:470-80.
46. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991;39:259-65.
47. Resch BE, Gaspar R, Sonkodi S, Falkay G. Vasoactive effects of erythropoietin on human placental blood vessels in vitro. Am J Obstet Gynecol 2003;188:993-6.
48. Olsen NV, Aachmann-Andersen NJ, Oturai P, Munch-Andersen T, Borno A, Hulston C et al. Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans. J Physiol 2011;589:1273-81.
49. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-9.
50. Tang YD, Rinder HM, Katz SD. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial. Am Heart J 2007;154:494.e1-7.
51. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
52. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
53. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-9.
54. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-41.
55. Liem A, van de Woestijne AP, Bruijns E, Roeters van Lennep HW, de Boo JA, van Halteren HK et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 2009;131:285-7.
56. Suh JW, Chung WY, Kim YS, Kim KI, Jeon EJ, Cho YS et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2011;149:216-20.
57. Prunier F, Biere L, Gilard M, Boschat J, Mouquet F, Bauchart JJ et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J 2012;163:200-7.e1.
58. Roubille F, Micheau A, Combes S, Thibaut S, Souteyrand G, Cayla G et al. Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial. Arch Cardiovasc Dis 2013;106:135-45.
59. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010;77:1020-30.